News
Investing.com -- Insmed Incorporated (NASDAQ:INSM) stock rose 6% Tuesday after the FDA approved BRINSUPRI (brensocatib), the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB ...
Hosted on MSN15d
Insmed announces FDA approval of Brinsupri for NCFB - MSN
“Brinsupri is the first and only FDA-approved treatment for NCFB, giving hundreds of thousands of patients and clinicians across the U.S. an option to manage this chronic and progressive disease ...
Investing.com -- Insmed Incorporated (NASDAQ: INSM) stock rose 6% Tuesday after the FDA approved BRINSUPRI (brensocatib), the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback